A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of AC-101 tablets in participants with moderate-to-severe ulcerative colitis. The total study duration is up to 17 weeks, including 4-week screening, 12-week treatment period, and 1-week safety follow-up. The study will enroll approximately 24 participants with moderate to severe active ulcerative colitis.

NCT Number	NCT07083193
Lead Sponsor	Accro Bioscience (Suzhou) Limited
Conditions	Ulcerative Colitis
Enrollment	24 participants
Start Date	2025-01-20
Primary Completion	2026-09-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2025-07-24